(Q42983450)

English

Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin

scientific article published on December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

author name string

Sheng-Shun Yang

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ming-Yang Lai

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ding-Shinn Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gran-Hum Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Jia-Horng Kao

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

426-433

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Recent advances in the molecular biology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

New schedules of interferon for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Variations within hepatitis C virus E2 protein and response to interferon treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Use and interpretation of virological tests for hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Avoiding false positives with PCR

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Interferon-induced and double-stranded RNA-activated enzymes: a specific protein kinase and 2',5'-oligoadenylate synthetases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Management of hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2003.00875.X

21 January 2018

Identifiers

10.1111/J.1478-3231.2003.00875.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42983450&oldid=2173321360"